Verona Pharma
Suite 21 - Alpha House
100 Borough High Street
London
SE1 1LB
United Kingdom
Tel: 44-0-20-7863-3300
Fax: 44-0-20-7863-3314
Website: http://www.veronapharma.com/
Email: info@veronapharma.com
206 articles about Verona Pharma
-
Data analytics firm GlobalData expects potential FDA approvals this year of Sanofi and Regeneron’s Dupixent and Verona’s ensifentrine to transform the treatment of chronic obstructive pulmonary disease.
-
Andrew Fisher Joins Verona Pharma as General Counsel
3/4/2024
Verona Pharma plc, announces Mr. Andrew Fisher has joined the Company as General Counsel, and member of the Executive Management Team.
-
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2/29/2024
Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2023, and provides a corporate update.
-
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
2/15/2024
Verona Pharma plc announces that it will report its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29, 2024 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
-
Michael Austwick Joins Verona Pharma as Non-Executive Director
2/1/2024
Verona Pharma plc announces Mr. Michael Austwick has joined the board as a Non-Executive Director.
-
Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Verona Pharma plc, announces that senior management will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 4:30 PM PST / 12:30 AM GMT.
-
Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital
1/2/2024
Verona Pharma plc, announces it and its wholly-owned subsidiary, Verona Pharma, Inc., have entered into a debt financing facility providing the Company with access to up to $400 million from funds managed by Oxford Finance LLC and Hercules Capital, Inc.
-
Verona Pharma has been given a leg up from two financial firms, Oxford Finance and Hercules Capital, securing a debt financing facility to support the potential launch of its COPD drug candidate ensifentrine.
-
Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award
11/17/2023
Verona Pharma plc, announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023’ at the SCRIP Awards in recognition of his exemplary leadership.
-
Verona Pharma Announces November 2023 Investor Conference Participation
11/8/2023
Verona Pharma plc, announces that senior management will present a company overview at the following conferences in November 2023.
-
Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/2/2023
Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the third quarter ended September 30, 2023, and provides a corporate update.
-
Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update
10/19/2023
Verona Pharma plc announces that it will report its financial results for the third quarter ended September 30, 2023 on Thursday, November 2, 2023 and host an investment community conference call at 9:00 a.m. EDT / 1:00 p.m. GMT to discuss these financial results and provide a corporate update.
-
Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023
10/6/2023
Verona Pharma plc, announces it will hold an Investor Update in New York City for investors and analysts on Wednesday, October 18, 2023, from 8:00 - 10:00 AM ET.
-
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023
10/3/2023
Verona Pharma plc, announces four presentations on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chronic obstructive pulmonary disease will be presented at CHEST Annual Meeting 2023.
-
Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD
9/11/2023
Verona Pharma plc, announces the US Food and Drug Administration has accepted for review the Company’s New Drug Application seeking approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease.
-
Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023
9/6/2023
Verona Pharma plc, announces an oral presentation on an additional analysis from its successful Phase 3 ENHANCE-1 study with ensifentrine for the treatment of chronic obstructive pulmonary disease will be presented at the European Respiratory Society International Congress 2023.
-
Christina Ackermann Joins Verona Pharma as Non-Executive Director
8/31/2023
Verona Pharma plc, announces effective September 1, 2023, Ms. Christina Ackermann will join the board as a Non-Executive Director.
-
Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/3/2023
Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the second quarter ended June 30, 2023, and provides a corporate update.
-
Verona Pharma to Present at 43rd Annual Canaccord Growth Conference
7/26/2023
Verona Pharma plc announces that senior management will present a company overview at the 43rd Annual Canaccord Growth Conference on Wednesday, August 9, 2023 at 12:00 PM EDT / 5:00 PM BST.
-
Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update
7/20/2023
Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the second quarter ended June 30, 2023 on Thursday, August 3, 2023 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m.